Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
about
Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingFour-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin.Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study.Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.A review of gliptins for 2014.Combination therapy when metformin is not an option for type 2 diabetes.The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes.iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets.A method for assessing real time rates of dissolution and absorption of carbohydrate and other food matrices in human subjects.iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know.Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes.
P2860
Q26992979-6236D2D5-F6EA-4018-B6C7-4552E4D6D486Q35846876-621E336F-B87F-4C60-91EB-17AD5E8C9F1CQ36220895-B253BC15-36ED-4D53-9F5C-DDCBDB4C7E3EQ36360065-E2CAB103-0A34-43E4-877A-A01646A42588Q36712701-72EE7BE6-41F5-419D-B426-D64E9ABA81A9Q38266290-8DA0D6E1-D549-4727-BD0C-4B2B22F0FB2CQ38377267-6535FCA8-B59A-4BAA-9DBC-0C7141E2E2EEQ38527885-2D9D29DD-B078-430A-BF54-5BB6ECEC0B06Q38560857-C83D2559-5BCE-4459-9212-BF6D9DBE5DC1Q38711727-B769F61D-9E0C-48D4-B5E2-9523984C580DQ38797551-B7D661EE-AC99-425A-9B66-C14C4A4EF1BCQ39027188-DEEB92CC-C5BF-4DAC-A85A-F03262FE90C5Q41388779-C94DA254-6798-436F-A607-DBE3775CD686Q42876331-11EC535D-BF65-4E4F-9FEA-6AA9564AC117Q50271509-E6F9343C-B92E-45B9-AEDE-FB8DEBED9AA8Q50894114-C0EE9F34-98F0-405E-89E0-3072AAB01489Q51259492-86415E57-1286-4CCB-9BA1-6CE9F11F7A53Q52568454-EC8D6C12-C923-4A4C-9CDF-58E3BA0AAB4EQ53396068-5A3659AC-4A68-4AAB-85EE-1728F72BF5BF
P2860
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
@en
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
@nl
type
label
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
@en
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
@nl
prefLabel
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
@en
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
@nl
P2860
P921
P356
P1476
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
@en
P2093
P2860
P356
10.4239/WJD.V5.I1.40
P577
2014-02-01T00:00:00Z